brand logo

Am Fam Physician. 2005;72(01):165-169

Congestive heart failure (CHF) is a common condition that has a poor prognosis despite recent advances. New treatments are needed to reduce sudden cardiac death in early and less-symptomatic cases and to reduce progressive failure and death among more symptomatic patients. Electrophysiologic treatments may be helpful because of intraventricular conduction disruptions occurring in heart failure. Atrial-synchronized biventricular pacing (cardiac resynchronization therapy) and implantable cardioverter-defibrillators (ICDs) have been studied for this purpose. ICDs clearly reduce mortality in patients with heart failure who have a history of ventricular arrhythmias. Cardiac resynchronization improves left ventricular filling time and reduces mitral regurgitation and septal dyskinesis, but a positive effect on mortality has not been demonstrated. McAlister and associates performed a systematic review examining the success rate, safety, and efficacy of biventricular pacemaker implantation.

Studies that investigated cardiac resynchronization therapy on patients with symptomatic heart failure were screened independently before inclusion in the review. Nine trials evaluating all-cause mortality met inclusion criteria. Cardiac resynchronization demonstrated significant mortality reduction with benefits apparent within three months of implantation.

Review of the seven trials that looked at progressive heart failure mortality favored cardiac resynchronization but did not reach statistical significance. Hospitalizations were reduced significantly among patients with New York Heart Association (NYHA) class III or IV symptoms who had undergone cardiac resynchronization therapy. NYHA functional class and quality of life also improved by at least one class with resynchronization. The use of beta blockers or digoxin (Lanoxin) did not affect the benefits of cardiac resynchronization therapy. One periprocedural death occurred for every 240 patients undergoing implantation, and over an average of six months, 7 percent of resynchronization devices malfunctioned, and leads dislodged in 9 percent.

The authors conclude that cardiac resynchronization therapy reduces all-cause mortality by 20 percent; heart failure hospitalizations among patients with class III and IV symptoms by 35 percent; and improves quality of life and functional status when added to medical therapy in patients with symptomatic CHF, prolonged QRS duration, and decreased left ventricular ejection fraction. Implantation of a biventricular pacemaker requires technical skill, and some may malfunction or be disrupted by lead dislodgement, but patient tolerability of the procedure is high. Cardiac resynchronization appears to be a useful adjunct in the management of patients with advanced CHF, but medical management and patient education remain the cornerstones of treatment.

Continue Reading


More in AFP

Copyright © 2005 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP.  See https://www.aafp.org/about/this-site/permissions.html for copyright questions and/or permission requests.